nodes	percent_of_prediction	percent_of_DWPC	metapath
Metoprolol—ABCB1—kidney cancer	0.263	1	CbGaD
Metoprolol—SLC22A2—Vinblastine—kidney cancer	0.0645	0.133	CbGbCtD
Metoprolol—ABCB1—Temsirolimus—kidney cancer	0.0571	0.118	CbGbCtD
Metoprolol—CYP2D6—Temsirolimus—kidney cancer	0.0538	0.111	CbGbCtD
Metoprolol—ABCB1—Pazopanib—kidney cancer	0.03	0.0619	CbGbCtD
Metoprolol—CYP2D6—Pazopanib—kidney cancer	0.0283	0.0584	CbGbCtD
Metoprolol—ABCB1—Dactinomycin—kidney cancer	0.0274	0.0566	CbGbCtD
Metoprolol—ABCB1—Gemcitabine—kidney cancer	0.0217	0.0448	CbGbCtD
Metoprolol—CYP2C19—Sorafenib—kidney cancer	0.0216	0.0445	CbGbCtD
Metoprolol—ABCB1—Erlotinib—kidney cancer	0.0214	0.0442	CbGbCtD
Metoprolol—CYP2D6—Erlotinib—kidney cancer	0.0202	0.0416	CbGbCtD
Metoprolol—ABCB1—Paclitaxel—kidney cancer	0.0196	0.0405	CbGbCtD
Metoprolol—ABCB1—Sorafenib—kidney cancer	0.0174	0.0359	CbGbCtD
Metoprolol—ABCB1—Vinblastine—kidney cancer	0.0172	0.0355	CbGbCtD
Metoprolol—ABCB1—Vincristine—kidney cancer	0.0169	0.0349	CbGbCtD
Metoprolol—CYP2D6—Sorafenib—kidney cancer	0.0164	0.0339	CbGbCtD
Metoprolol—CYP2D6—Vinblastine—kidney cancer	0.0162	0.0334	CbGbCtD
Metoprolol—ABCB1—Sunitinib—kidney cancer	0.0141	0.0291	CbGbCtD
Metoprolol—ABCB1—Doxorubicin—kidney cancer	0.0106	0.0218	CbGbCtD
Metoprolol—CYP2D6—Doxorubicin—kidney cancer	0.00995	0.0205	CbGbCtD
Metoprolol—SLC22A2—nephron—kidney cancer	0.00922	0.34	CbGeAlD
Metoprolol—CYP2C19—urine—kidney cancer	0.00402	0.149	CbGeAlD
Metoprolol—CYP2D6—urine—kidney cancer	0.00234	0.0865	CbGeAlD
Metoprolol—SLC22A2—nephron tubule—kidney cancer	0.00199	0.0735	CbGeAlD
Metoprolol—SLC22A2—renal system—kidney cancer	0.00181	0.0668	CbGeAlD
Metoprolol—SLC22A2—kidney—kidney cancer	0.00175	0.0646	CbGeAlD
Metoprolol—SLC22A2—cortex of kidney—kidney cancer	0.0017	0.0629	CbGeAlD
Metoprolol—ADRB1—cardiac atrium—kidney cancer	0.0011	0.0407	CbGeAlD
Metoprolol—Chlorphenesin—BCHE—kidney cancer	0.000746	0.376	CrCbGaD
Metoprolol—CYP2D6—renal system—kidney cancer	0.000573	0.0212	CbGeAlD
Metoprolol—CYP2D6—kidney—kidney cancer	0.000554	0.0205	CbGeAlD
Metoprolol—ABCB1—nephron tubule—kidney cancer	0.000453	0.0167	CbGeAlD
Metoprolol—ABCB1—renal system—kidney cancer	0.000412	0.0152	CbGeAlD
Metoprolol—ABCB1—kidney—kidney cancer	0.000398	0.0147	CbGeAlD
Metoprolol—ABCB1—cortex of kidney—kidney cancer	0.000388	0.0143	CbGeAlD
Metoprolol—ABCB1—gonad—kidney cancer	0.00037	0.0136	CbGeAlD
Metoprolol—Chlorphenesin—PTGS2—kidney cancer	0.000344	0.173	CrCbGaD
Metoprolol—Atenolol—ABCB1—kidney cancer	0.000292	0.147	CrCbGaD
Metoprolol—Acebutolol—ABCB1—kidney cancer	0.00027	0.136	CrCbGaD
Metoprolol—Propranolol—CYP1A1—kidney cancer	0.000216	0.109	CrCbGaD
Metoprolol—Syncope—Paclitaxel—kidney cancer	0.000145	0.000671	CcSEcCtD
Metoprolol—Cerebrovascular accident—Doxorubicin—kidney cancer	0.000145	0.000671	CcSEcCtD
Metoprolol—Leukopenia—Paclitaxel—kidney cancer	0.000145	0.00067	CcSEcCtD
Metoprolol—Hypersensitivity—Sunitinib—kidney cancer	0.000145	0.00067	CcSEcCtD
Metoprolol—Pruritus—Sorafenib—kidney cancer	0.000145	0.000669	CcSEcCtD
Metoprolol—Vomiting—Erlotinib—kidney cancer	0.000144	0.000668	CcSEcCtD
Metoprolol—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.000144	0.000665	CcSEcCtD
Metoprolol—Gastrointestinal disorder—Vincristine—kidney cancer	0.000144	0.000664	CcSEcCtD
Metoprolol—Fatigue—Vincristine—kidney cancer	0.000143	0.000663	CcSEcCtD
Metoprolol—Rash—Erlotinib—kidney cancer	0.000143	0.000662	CcSEcCtD
Metoprolol—Dermatitis—Erlotinib—kidney cancer	0.000143	0.000662	CcSEcCtD
Metoprolol—Palpitations—Paclitaxel—kidney cancer	0.000143	0.000662	CcSEcCtD
Metoprolol—Insomnia—Gemcitabine—kidney cancer	0.000143	0.00066	CcSEcCtD
Metoprolol—Eye disorder—Capecitabine—kidney cancer	0.000143	0.00066	CcSEcCtD
Metoprolol—Headache—Erlotinib—kidney cancer	0.000142	0.000658	CcSEcCtD
Metoprolol—Tinnitus—Capecitabine—kidney cancer	0.000142	0.000658	CcSEcCtD
Metoprolol—Loss of consciousness—Paclitaxel—kidney cancer	0.000142	0.000658	CcSEcCtD
Metoprolol—Constipation—Vincristine—kidney cancer	0.000142	0.000658	CcSEcCtD
Metoprolol—Pain—Vincristine—kidney cancer	0.000142	0.000658	CcSEcCtD
Metoprolol—Paraesthesia—Gemcitabine—kidney cancer	0.000142	0.000655	CcSEcCtD
Metoprolol—Cardiac disorder—Capecitabine—kidney cancer	0.000142	0.000655	CcSEcCtD
Metoprolol—Asthenia—Sunitinib—kidney cancer	0.000141	0.000653	CcSEcCtD
Metoprolol—Dyspnoea—Gemcitabine—kidney cancer	0.000141	0.000651	CcSEcCtD
Metoprolol—Nausea—Vinblastine—kidney cancer	0.00014	0.000649	CcSEcCtD
Metoprolol—Somnolence—Gemcitabine—kidney cancer	0.00014	0.000649	CcSEcCtD
Metoprolol—Affect lability—Doxorubicin—kidney cancer	0.00014	0.000647	CcSEcCtD
Metoprolol—Nausea—Everolimus—kidney cancer	0.00014	0.000647	CcSEcCtD
Metoprolol—Diarrhoea—Sorafenib—kidney cancer	0.00014	0.000647	CcSEcCtD
Metoprolol—Hypertension—Paclitaxel—kidney cancer	0.00014	0.000646	CcSEcCtD
Metoprolol—Pruritus—Sunitinib—kidney cancer	0.000139	0.000644	CcSEcCtD
Metoprolol—Angiopathy—Capecitabine—kidney cancer	0.000138	0.00064	CcSEcCtD
Metoprolol—Immune system disorder—Capecitabine—kidney cancer	0.000138	0.000638	CcSEcCtD
Metoprolol—Arthralgia—Paclitaxel—kidney cancer	0.000138	0.000637	CcSEcCtD
Metoprolol—Chest pain—Paclitaxel—kidney cancer	0.000138	0.000637	CcSEcCtD
Metoprolol—Mediastinal disorder—Capecitabine—kidney cancer	0.000137	0.000636	CcSEcCtD
Metoprolol—Anxiety—Paclitaxel—kidney cancer	0.000137	0.000635	CcSEcCtD
Metoprolol—Hypersensitivity—Dactinomycin—kidney cancer	0.000137	0.000634	CcSEcCtD
Metoprolol—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000137	0.000633	CcSEcCtD
Metoprolol—Arrhythmia—Capecitabine—kidney cancer	0.000136	0.000631	CcSEcCtD
Metoprolol—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000136	0.00063	CcSEcCtD
Metoprolol—Fatigue—Gemcitabine—kidney cancer	0.000136	0.000629	CcSEcCtD
Metoprolol—Gastrointestinal pain—Vincristine—kidney cancer	0.000136	0.000629	CcSEcCtD
Metoprolol—Cardiac arrest—Doxorubicin—kidney cancer	0.000135	0.000625	CcSEcCtD
Metoprolol—Dizziness—Sorafenib—kidney cancer	0.000135	0.000625	CcSEcCtD
Metoprolol—Constipation—Gemcitabine—kidney cancer	0.000135	0.000624	CcSEcCtD
Metoprolol—Pain—Gemcitabine—kidney cancer	0.000135	0.000624	CcSEcCtD
Metoprolol—Nausea—Erlotinib—kidney cancer	0.000135	0.000624	CcSEcCtD
Metoprolol—Alopecia—Capecitabine—kidney cancer	0.000135	0.000624	CcSEcCtD
Metoprolol—Dry mouth—Paclitaxel—kidney cancer	0.000135	0.000623	CcSEcCtD
Metoprolol—Mood swings—Doxorubicin—kidney cancer	0.000135	0.000623	CcSEcCtD
Metoprolol—Diarrhoea—Sunitinib—kidney cancer	0.000134	0.000622	CcSEcCtD
Metoprolol—Mental disorder—Capecitabine—kidney cancer	0.000134	0.000618	CcSEcCtD
Metoprolol—Asthenia—Dactinomycin—kidney cancer	0.000133	0.000618	CcSEcCtD
Metoprolol—Confusional state—Paclitaxel—kidney cancer	0.000133	0.000616	CcSEcCtD
Metoprolol—Oedema—Paclitaxel—kidney cancer	0.000132	0.000611	CcSEcCtD
Metoprolol—Abdominal pain—Vincristine—kidney cancer	0.000131	0.000608	CcSEcCtD
Metoprolol—Body temperature increased—Vincristine—kidney cancer	0.000131	0.000608	CcSEcCtD
Metoprolol—Liver function test abnormal—Doxorubicin—kidney cancer	0.000131	0.000607	CcSEcCtD
Metoprolol—Flatulence—Capecitabine—kidney cancer	0.000131	0.000605	CcSEcCtD
Metoprolol—Dysgeusia—Capecitabine—kidney cancer	0.00013	0.000602	CcSEcCtD
Metoprolol—Dizziness—Sunitinib—kidney cancer	0.00013	0.000601	CcSEcCtD
Metoprolol—Feeling abnormal—Gemcitabine—kidney cancer	0.00013	0.000601	CcSEcCtD
Metoprolol—Shock—Paclitaxel—kidney cancer	0.00013	0.000601	CcSEcCtD
Metoprolol—Vomiting—Sorafenib—kidney cancer	0.00013	0.000601	CcSEcCtD
Metoprolol—Abdominal pain upper—Doxorubicin—kidney cancer	0.00013	0.000601	CcSEcCtD
Metoprolol—Orthostatic hypotension—Doxorubicin—kidney cancer	0.00013	0.000601	CcSEcCtD
Metoprolol—Nervous system disorder—Paclitaxel—kidney cancer	0.000129	0.000599	CcSEcCtD
Metoprolol—Thrombocytopenia—Paclitaxel—kidney cancer	0.000129	0.000598	CcSEcCtD
Metoprolol—Tachycardia—Paclitaxel—kidney cancer	0.000129	0.000596	CcSEcCtD
Metoprolol—Rash—Sorafenib—kidney cancer	0.000129	0.000596	CcSEcCtD
Metoprolol—Dermatitis—Sorafenib—kidney cancer	0.000129	0.000595	CcSEcCtD
Metoprolol—Breast disorder—Doxorubicin—kidney cancer	0.000128	0.000594	CcSEcCtD
Metoprolol—Skin disorder—Paclitaxel—kidney cancer	0.000128	0.000594	CcSEcCtD
Metoprolol—Headache—Sorafenib—kidney cancer	0.000128	0.000592	CcSEcCtD
Metoprolol—Muscle spasms—Capecitabine—kidney cancer	0.000128	0.000591	CcSEcCtD
Metoprolol—Hyperhidrosis—Paclitaxel—kidney cancer	0.000128	0.000591	CcSEcCtD
Metoprolol—Diarrhoea—Dactinomycin—kidney cancer	0.000127	0.000589	CcSEcCtD
Metoprolol—Vision blurred—Capecitabine—kidney cancer	0.000125	0.000579	CcSEcCtD
Metoprolol—Vomiting—Sunitinib—kidney cancer	0.000125	0.000578	CcSEcCtD
Metoprolol—Body temperature increased—Gemcitabine—kidney cancer	0.000125	0.000577	CcSEcCtD
Metoprolol—Rash—Sunitinib—kidney cancer	0.000124	0.000574	CcSEcCtD
Metoprolol—Dermatitis—Sunitinib—kidney cancer	0.000124	0.000573	CcSEcCtD
Metoprolol—Hypotension—Paclitaxel—kidney cancer	0.000123	0.000571	CcSEcCtD
Metoprolol—Headache—Sunitinib—kidney cancer	0.000123	0.00057	CcSEcCtD
Metoprolol—Hypersensitivity—Vincristine—kidney cancer	0.000122	0.000567	CcSEcCtD
Metoprolol—Nausea—Sorafenib—kidney cancer	0.000121	0.000561	CcSEcCtD
Metoprolol—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.00012	0.000557	CcSEcCtD
Metoprolol—Angina pectoris—Doxorubicin—kidney cancer	0.00012	0.000554	CcSEcCtD
Metoprolol—Insomnia—Paclitaxel—kidney cancer	0.000119	0.000553	CcSEcCtD
Metoprolol—Vertigo—Capecitabine—kidney cancer	0.000119	0.000552	CcSEcCtD
Metoprolol—Asthenia—Vincristine—kidney cancer	0.000119	0.000552	CcSEcCtD
Metoprolol—Syncope—Capecitabine—kidney cancer	0.000119	0.000551	CcSEcCtD
Metoprolol—Leukopenia—Capecitabine—kidney cancer	0.000119	0.00055	CcSEcCtD
Metoprolol—Paraesthesia—Paclitaxel—kidney cancer	0.000119	0.000549	CcSEcCtD
Metoprolol—Vomiting—Dactinomycin—kidney cancer	0.000118	0.000547	CcSEcCtD
Metoprolol—Dyspnoea—Paclitaxel—kidney cancer	0.000118	0.000545	CcSEcCtD
Metoprolol—Somnolence—Paclitaxel—kidney cancer	0.000117	0.000543	CcSEcCtD
Metoprolol—Palpitations—Capecitabine—kidney cancer	0.000117	0.000543	CcSEcCtD
Metoprolol—Rash—Dactinomycin—kidney cancer	0.000117	0.000543	CcSEcCtD
Metoprolol—Nausea—Sunitinib—kidney cancer	0.000117	0.00054	CcSEcCtD
Metoprolol—Loss of consciousness—Capecitabine—kidney cancer	0.000117	0.00054	CcSEcCtD
Metoprolol—Dyspepsia—Paclitaxel—kidney cancer	0.000116	0.000538	CcSEcCtD
Metoprolol—Propranolol—ABCB1—kidney cancer	0.000115	0.058	CrCbGaD
Metoprolol—Hypertension—Capecitabine—kidney cancer	0.000115	0.00053	CcSEcCtD
Metoprolol—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000114	0.000528	CcSEcCtD
Metoprolol—Fatigue—Paclitaxel—kidney cancer	0.000114	0.000527	CcSEcCtD
Metoprolol—Diarrhoea—Vincristine—kidney cancer	0.000114	0.000526	CcSEcCtD
Metoprolol—Asthenia—Gemcitabine—kidney cancer	0.000113	0.000524	CcSEcCtD
Metoprolol—Chest pain—Capecitabine—kidney cancer	0.000113	0.000523	CcSEcCtD
Metoprolol—Arthralgia—Capecitabine—kidney cancer	0.000113	0.000523	CcSEcCtD
Metoprolol—Pain—Paclitaxel—kidney cancer	0.000113	0.000523	CcSEcCtD
Metoprolol—Constipation—Paclitaxel—kidney cancer	0.000113	0.000523	CcSEcCtD
Metoprolol—Anxiety—Capecitabine—kidney cancer	0.000113	0.000521	CcSEcCtD
Metoprolol—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000112	0.000519	CcSEcCtD
Metoprolol—Photosensitivity reaction—Doxorubicin—kidney cancer	0.000112	0.000519	CcSEcCtD
Metoprolol—Weight increased—Doxorubicin—kidney cancer	0.000112	0.000517	CcSEcCtD
Metoprolol—Pruritus—Gemcitabine—kidney cancer	0.000112	0.000516	CcSEcCtD
Metoprolol—Dry mouth—Capecitabine—kidney cancer	0.000111	0.000512	CcSEcCtD
Metoprolol—Nausea—Dactinomycin—kidney cancer	0.000111	0.000511	CcSEcCtD
Metoprolol—Pneumonia—Doxorubicin—kidney cancer	0.00011	0.00051	CcSEcCtD
Metoprolol—Dizziness—Vincristine—kidney cancer	0.00011	0.000509	CcSEcCtD
Metoprolol—Confusional state—Capecitabine—kidney cancer	0.000109	0.000506	CcSEcCtD
Metoprolol—Feeling abnormal—Paclitaxel—kidney cancer	0.000109	0.000504	CcSEcCtD
Metoprolol—Oedema—Capecitabine—kidney cancer	0.000108	0.000501	CcSEcCtD
Metoprolol—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000108	0.0005	CcSEcCtD
Metoprolol—Diarrhoea—Gemcitabine—kidney cancer	0.000108	0.000499	CcSEcCtD
Metoprolol—Jaundice—Doxorubicin—kidney cancer	0.000107	0.000494	CcSEcCtD
Metoprolol—Shock—Capecitabine—kidney cancer	0.000107	0.000493	CcSEcCtD
Metoprolol—Conjunctivitis—Doxorubicin—kidney cancer	0.000106	0.000493	CcSEcCtD
Metoprolol—Nervous system disorder—Capecitabine—kidney cancer	0.000106	0.000492	CcSEcCtD
Metoprolol—Thrombocytopenia—Capecitabine—kidney cancer	0.000106	0.000491	CcSEcCtD
Metoprolol—Tachycardia—Capecitabine—kidney cancer	0.000106	0.000489	CcSEcCtD
Metoprolol—Vomiting—Vincristine—kidney cancer	0.000106	0.000489	CcSEcCtD
Metoprolol—Skin disorder—Capecitabine—kidney cancer	0.000105	0.000487	CcSEcCtD
Metoprolol—Sweating—Doxorubicin—kidney cancer	0.000105	0.000486	CcSEcCtD
Metoprolol—Urticaria—Paclitaxel—kidney cancer	0.000105	0.000485	CcSEcCtD
Metoprolol—Rash—Vincristine—kidney cancer	0.000105	0.000485	CcSEcCtD
Metoprolol—Hyperhidrosis—Capecitabine—kidney cancer	0.000105	0.000485	CcSEcCtD
Metoprolol—Dermatitis—Vincristine—kidney cancer	0.000105	0.000485	CcSEcCtD
Metoprolol—Abdominal pain—Paclitaxel—kidney cancer	0.000104	0.000483	CcSEcCtD
Metoprolol—Body temperature increased—Paclitaxel—kidney cancer	0.000104	0.000483	CcSEcCtD
Metoprolol—Headache—Vincristine—kidney cancer	0.000104	0.000482	CcSEcCtD
Metoprolol—Hepatobiliary disease—Doxorubicin—kidney cancer	0.000104	0.000479	CcSEcCtD
Metoprolol—Agranulocytosis—Doxorubicin—kidney cancer	0.000102	0.000473	CcSEcCtD
Metoprolol—Hypotension—Capecitabine—kidney cancer	0.000101	0.000469	CcSEcCtD
Metoprolol—Vomiting—Gemcitabine—kidney cancer	0.0001	0.000464	CcSEcCtD
Metoprolol—Bradycardia—Doxorubicin—kidney cancer	0.0001	0.000463	CcSEcCtD
Metoprolol—Rash—Gemcitabine—kidney cancer	9.94e-05	0.00046	CcSEcCtD
Metoprolol—Dermatitis—Gemcitabine—kidney cancer	9.93e-05	0.00046	CcSEcCtD
Metoprolol—Headache—Gemcitabine—kidney cancer	9.88e-05	0.000457	CcSEcCtD
Metoprolol—Nausea—Vincristine—kidney cancer	9.87e-05	0.000457	CcSEcCtD
Metoprolol—Musculoskeletal discomfort—Capecitabine—kidney cancer	9.87e-05	0.000457	CcSEcCtD
Metoprolol—Rhinitis—Doxorubicin—kidney cancer	9.86e-05	0.000456	CcSEcCtD
Metoprolol—Hepatitis—Doxorubicin—kidney cancer	9.83e-05	0.000455	CcSEcCtD
Metoprolol—Insomnia—Capecitabine—kidney cancer	9.8e-05	0.000454	CcSEcCtD
Metoprolol—Paraesthesia—Capecitabine—kidney cancer	9.73e-05	0.00045	CcSEcCtD
Metoprolol—Hypersensitivity—Paclitaxel—kidney cancer	9.73e-05	0.00045	CcSEcCtD
Metoprolol—Oedema peripheral—Doxorubicin—kidney cancer	9.68e-05	0.000448	CcSEcCtD
Metoprolol—Connective tissue disorder—Doxorubicin—kidney cancer	9.66e-05	0.000447	CcSEcCtD
Metoprolol—Dyspnoea—Capecitabine—kidney cancer	9.66e-05	0.000447	CcSEcCtD
Metoprolol—Dyspepsia—Capecitabine—kidney cancer	9.54e-05	0.000441	CcSEcCtD
Metoprolol—Visual impairment—Doxorubicin—kidney cancer	9.47e-05	0.000438	CcSEcCtD
Metoprolol—Asthenia—Paclitaxel—kidney cancer	9.47e-05	0.000438	CcSEcCtD
Metoprolol—Nausea—Gemcitabine—kidney cancer	9.37e-05	0.000434	CcSEcCtD
Metoprolol—Gastrointestinal disorder—Capecitabine—kidney cancer	9.35e-05	0.000433	CcSEcCtD
Metoprolol—Fatigue—Capecitabine—kidney cancer	9.34e-05	0.000432	CcSEcCtD
Metoprolol—Pruritus—Paclitaxel—kidney cancer	9.34e-05	0.000432	CcSEcCtD
Metoprolol—Pain—Capecitabine—kidney cancer	9.27e-05	0.000429	CcSEcCtD
Metoprolol—Constipation—Capecitabine—kidney cancer	9.27e-05	0.000429	CcSEcCtD
Metoprolol—Eye disorder—Doxorubicin—kidney cancer	9.19e-05	0.000425	CcSEcCtD
Metoprolol—Tinnitus—Doxorubicin—kidney cancer	9.17e-05	0.000424	CcSEcCtD
Metoprolol—Cardiac disorder—Doxorubicin—kidney cancer	9.12e-05	0.000422	CcSEcCtD
Metoprolol—Diarrhoea—Paclitaxel—kidney cancer	9.03e-05	0.000418	CcSEcCtD
Metoprolol—Feeling abnormal—Capecitabine—kidney cancer	8.93e-05	0.000413	CcSEcCtD
Metoprolol—Angiopathy—Doxorubicin—kidney cancer	8.92e-05	0.000413	CcSEcCtD
Metoprolol—Immune system disorder—Doxorubicin—kidney cancer	8.88e-05	0.000411	CcSEcCtD
Metoprolol—Gastrointestinal pain—Capecitabine—kidney cancer	8.86e-05	0.00041	CcSEcCtD
Metoprolol—Mediastinal disorder—Doxorubicin—kidney cancer	8.86e-05	0.00041	CcSEcCtD
Metoprolol—Arrhythmia—Doxorubicin—kidney cancer	8.78e-05	0.000406	CcSEcCtD
Metoprolol—Dizziness—Paclitaxel—kidney cancer	8.73e-05	0.000404	CcSEcCtD
Metoprolol—Alopecia—Doxorubicin—kidney cancer	8.69e-05	0.000402	CcSEcCtD
Metoprolol—Mental disorder—Doxorubicin—kidney cancer	8.61e-05	0.000399	CcSEcCtD
Metoprolol—Urticaria—Capecitabine—kidney cancer	8.61e-05	0.000398	CcSEcCtD
Metoprolol—Abdominal pain—Capecitabine—kidney cancer	8.57e-05	0.000396	CcSEcCtD
Metoprolol—Body temperature increased—Capecitabine—kidney cancer	8.57e-05	0.000396	CcSEcCtD
Metoprolol—Flatulence—Doxorubicin—kidney cancer	8.43e-05	0.00039	CcSEcCtD
Metoprolol—Tension—Doxorubicin—kidney cancer	8.4e-05	0.000389	CcSEcCtD
Metoprolol—Vomiting—Paclitaxel—kidney cancer	8.39e-05	0.000389	CcSEcCtD
Metoprolol—Dysgeusia—Doxorubicin—kidney cancer	8.38e-05	0.000388	CcSEcCtD
Metoprolol—Rash—Paclitaxel—kidney cancer	8.32e-05	0.000385	CcSEcCtD
Metoprolol—Dermatitis—Paclitaxel—kidney cancer	8.32e-05	0.000385	CcSEcCtD
Metoprolol—Nervousness—Doxorubicin—kidney cancer	8.31e-05	0.000385	CcSEcCtD
Metoprolol—Headache—Paclitaxel—kidney cancer	8.27e-05	0.000383	CcSEcCtD
Metoprolol—Muscle spasms—Doxorubicin—kidney cancer	8.23e-05	0.000381	CcSEcCtD
Metoprolol—Vision blurred—Doxorubicin—kidney cancer	8.07e-05	0.000373	CcSEcCtD
Metoprolol—Hypersensitivity—Capecitabine—kidney cancer	7.98e-05	0.000369	CcSEcCtD
Metoprolol—Nausea—Paclitaxel—kidney cancer	7.84e-05	0.000363	CcSEcCtD
Metoprolol—Asthenia—Capecitabine—kidney cancer	7.77e-05	0.00036	CcSEcCtD
Metoprolol—Vertigo—Doxorubicin—kidney cancer	7.69e-05	0.000356	CcSEcCtD
Metoprolol—Syncope—Doxorubicin—kidney cancer	7.67e-05	0.000355	CcSEcCtD
Metoprolol—Pruritus—Capecitabine—kidney cancer	7.67e-05	0.000355	CcSEcCtD
Metoprolol—Leukopenia—Doxorubicin—kidney cancer	7.66e-05	0.000355	CcSEcCtD
Metoprolol—Palpitations—Doxorubicin—kidney cancer	7.56e-05	0.00035	CcSEcCtD
Metoprolol—Loss of consciousness—Doxorubicin—kidney cancer	7.52e-05	0.000348	CcSEcCtD
Metoprolol—Diarrhoea—Capecitabine—kidney cancer	7.41e-05	0.000343	CcSEcCtD
Metoprolol—Hypertension—Doxorubicin—kidney cancer	7.39e-05	0.000342	CcSEcCtD
Metoprolol—Arthralgia—Doxorubicin—kidney cancer	7.29e-05	0.000337	CcSEcCtD
Metoprolol—Chest pain—Doxorubicin—kidney cancer	7.29e-05	0.000337	CcSEcCtD
Metoprolol—Anxiety—Doxorubicin—kidney cancer	7.26e-05	0.000336	CcSEcCtD
Metoprolol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	7.24e-05	0.000335	CcSEcCtD
Metoprolol—Dizziness—Capecitabine—kidney cancer	7.17e-05	0.000332	CcSEcCtD
Metoprolol—Dry mouth—Doxorubicin—kidney cancer	7.13e-05	0.00033	CcSEcCtD
Metoprolol—Confusional state—Doxorubicin—kidney cancer	7.04e-05	0.000326	CcSEcCtD
Metoprolol—Oedema—Doxorubicin—kidney cancer	6.98e-05	0.000323	CcSEcCtD
Metoprolol—Vomiting—Capecitabine—kidney cancer	6.89e-05	0.000319	CcSEcCtD
Metoprolol—Shock—Doxorubicin—kidney cancer	6.87e-05	0.000318	CcSEcCtD
Metoprolol—Nervous system disorder—Doxorubicin—kidney cancer	6.85e-05	0.000317	CcSEcCtD
Metoprolol—Thrombocytopenia—Doxorubicin—kidney cancer	6.84e-05	0.000316	CcSEcCtD
Metoprolol—Rash—Capecitabine—kidney cancer	6.83e-05	0.000316	CcSEcCtD
Metoprolol—Dermatitis—Capecitabine—kidney cancer	6.83e-05	0.000316	CcSEcCtD
Metoprolol—Tachycardia—Doxorubicin—kidney cancer	6.82e-05	0.000315	CcSEcCtD
Metoprolol—Headache—Capecitabine—kidney cancer	6.79e-05	0.000314	CcSEcCtD
Metoprolol—Skin disorder—Doxorubicin—kidney cancer	6.78e-05	0.000314	CcSEcCtD
Metoprolol—Hyperhidrosis—Doxorubicin—kidney cancer	6.75e-05	0.000312	CcSEcCtD
Metoprolol—Hypotension—Doxorubicin—kidney cancer	6.53e-05	0.000302	CcSEcCtD
Metoprolol—Nausea—Capecitabine—kidney cancer	6.44e-05	0.000298	CcSEcCtD
Metoprolol—Musculoskeletal discomfort—Doxorubicin—kidney cancer	6.36e-05	0.000294	CcSEcCtD
Metoprolol—Insomnia—Doxorubicin—kidney cancer	6.32e-05	0.000292	CcSEcCtD
Metoprolol—Paraesthesia—Doxorubicin—kidney cancer	6.27e-05	0.00029	CcSEcCtD
Metoprolol—Dyspnoea—Doxorubicin—kidney cancer	6.23e-05	0.000288	CcSEcCtD
Metoprolol—Somnolence—Doxorubicin—kidney cancer	6.21e-05	0.000287	CcSEcCtD
Metoprolol—Dyspepsia—Doxorubicin—kidney cancer	6.15e-05	0.000285	CcSEcCtD
Metoprolol—Gastrointestinal disorder—Doxorubicin—kidney cancer	6.03e-05	0.000279	CcSEcCtD
Metoprolol—Fatigue—Doxorubicin—kidney cancer	6.02e-05	0.000279	CcSEcCtD
Metoprolol—Pain—Doxorubicin—kidney cancer	5.97e-05	0.000276	CcSEcCtD
Metoprolol—Constipation—Doxorubicin—kidney cancer	5.97e-05	0.000276	CcSEcCtD
Metoprolol—Feeling abnormal—Doxorubicin—kidney cancer	5.76e-05	0.000266	CcSEcCtD
Metoprolol—Gastrointestinal pain—Doxorubicin—kidney cancer	5.71e-05	0.000264	CcSEcCtD
Metoprolol—Urticaria—Doxorubicin—kidney cancer	5.55e-05	0.000257	CcSEcCtD
Metoprolol—Body temperature increased—Doxorubicin—kidney cancer	5.52e-05	0.000256	CcSEcCtD
Metoprolol—Abdominal pain—Doxorubicin—kidney cancer	5.52e-05	0.000256	CcSEcCtD
Metoprolol—Hypersensitivity—Doxorubicin—kidney cancer	5.15e-05	0.000238	CcSEcCtD
Metoprolol—Asthenia—Doxorubicin—kidney cancer	5.01e-05	0.000232	CcSEcCtD
Metoprolol—Pruritus—Doxorubicin—kidney cancer	4.94e-05	0.000229	CcSEcCtD
Metoprolol—Diarrhoea—Doxorubicin—kidney cancer	4.78e-05	0.000221	CcSEcCtD
Metoprolol—Dizziness—Doxorubicin—kidney cancer	4.62e-05	0.000214	CcSEcCtD
Metoprolol—Vomiting—Doxorubicin—kidney cancer	4.44e-05	0.000206	CcSEcCtD
Metoprolol—Rash—Doxorubicin—kidney cancer	4.4e-05	0.000204	CcSEcCtD
Metoprolol—Dermatitis—Doxorubicin—kidney cancer	4.4e-05	0.000204	CcSEcCtD
Metoprolol—Headache—Doxorubicin—kidney cancer	4.38e-05	0.000202	CcSEcCtD
Metoprolol—Nausea—Doxorubicin—kidney cancer	4.15e-05	0.000192	CcSEcCtD
Metoprolol—SLC22A2—Metabolism—CA9—kidney cancer	8.14e-06	0.00109	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—SFRP2—kidney cancer	8.07e-06	0.00108	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—ANXA1—kidney cancer	8.03e-06	0.00108	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PDHB—kidney cancer	7.98e-06	0.00107	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—CCBL1—kidney cancer	7.96e-06	0.00107	CbGpPWpGaD
Metoprolol—CYP2D6—Biological oxidations—POMC—kidney cancer	7.96e-06	0.00107	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—ANXA1—kidney cancer	7.85e-06	0.00105	CbGpPWpGaD
Metoprolol—SLC22A2—Transmission across Chemical Synapses—MAPK1—kidney cancer	7.75e-06	0.00104	CbGpPWpGaD
Metoprolol—ADRB1—GPCR ligand binding—POMC—kidney cancer	7.66e-06	0.00103	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—CCBL1—kidney cancer	7.5e-06	0.00101	CbGpPWpGaD
Metoprolol—ADRB2—GPCR ligand binding—POMC—kidney cancer	7.49e-06	0.00101	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	7.38e-06	0.00099	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—GLIPR1—kidney cancer	7.07e-06	0.000949	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PPAT—kidney cancer	7.07e-06	0.000949	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	6.98e-06	0.000937	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—CRABP1—kidney cancer	6.93e-06	0.000929	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	6.91e-06	0.000927	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—GLIPR1—kidney cancer	6.9e-06	0.000926	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PPAT—kidney cancer	6.9e-06	0.000926	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—AKAP13—kidney cancer	6.65e-06	0.000892	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CASP2—kidney cancer	6.65e-06	0.000892	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—FH—kidney cancer	6.58e-06	0.000882	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—APRT—kidney cancer	6.58e-06	0.000882	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CASP2—kidney cancer	6.51e-06	0.000873	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—AKAP13—kidney cancer	6.51e-06	0.000873	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—GLIPR1—kidney cancer	6.51e-06	0.000873	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PPAT—kidney cancer	6.51e-06	0.000873	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—ITPR2—kidney cancer	6.44e-06	0.000863	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	6.43e-06	0.000862	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—APRT—kidney cancer	6.42e-06	0.000861	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—FH—kidney cancer	6.42e-06	0.000861	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—kidney cancer	6.4e-06	0.000859	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—kidney cancer	6.33e-06	0.000849	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—kidney cancer	6.19e-06	0.000831	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—GPC3—kidney cancer	6.18e-06	0.000829	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—GRB7—kidney cancer	6.09e-06	0.000816	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—APRT—kidney cancer	6.05e-06	0.000811	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—FH—kidney cancer	6.05e-06	0.000811	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—GPC3—kidney cancer	6.04e-06	0.000809	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—CA2—kidney cancer	6.02e-06	0.000807	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—GRB7—kidney cancer	5.95e-06	0.000798	CbGpPWpGaD
Metoprolol—SLC22A2—Neuronal System—MAPK1—kidney cancer	5.94e-06	0.000796	CbGpPWpGaD
Metoprolol—ABCB1—Transmembrane transport of small molecules—SLC5A5—kidney cancer	5.89e-06	0.00079	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—CA2—kidney cancer	5.87e-06	0.000787	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—ACHE—kidney cancer	5.87e-06	0.000787	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—GSTT1—kidney cancer	5.87e-06	0.000787	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—kidney cancer	5.87e-06	0.000787	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—ALAD—kidney cancer	5.86e-06	0.000786	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—ST3GAL2—kidney cancer	5.72e-06	0.000767	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—ALAD—kidney cancer	5.72e-06	0.000767	CbGpPWpGaD
Metoprolol—ABCB1—Transmembrane transport of small molecules—SLC2A1—kidney cancer	5.69e-06	0.000763	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—GPC3—kidney cancer	5.69e-06	0.000763	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—ITPR2—kidney cancer	5.66e-06	0.000759	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—kidney cancer	5.6e-06	0.00075	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—ALDH1A1—kidney cancer	5.59e-06	0.00075	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—ST3GAL2—kidney cancer	5.58e-06	0.000749	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—kidney cancer	5.58e-06	0.000749	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—SCARB1—kidney cancer	5.56e-06	0.000745	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—kidney cancer	5.54e-06	0.000743	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—ITPR2—kidney cancer	5.53e-06	0.000742	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—CA2—kidney cancer	5.53e-06	0.000742	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—PTGS1—kidney cancer	5.5e-06	0.000738	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—ALDH1A1—kidney cancer	5.46e-06	0.000732	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—kidney cancer	5.4e-06	0.000724	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—PSMD7—kidney cancer	5.4e-06	0.000724	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—ALAD—kidney cancer	5.39e-06	0.000723	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PGK1—kidney cancer	5.36e-06	0.000719	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—SLC5A3—kidney cancer	5.36e-06	0.000719	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—ST3GAL2—kidney cancer	5.26e-06	0.000706	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—LDHB—kidney cancer	5.26e-06	0.000705	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PGK1—kidney cancer	5.23e-06	0.000702	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—SLC5A3—kidney cancer	5.23e-06	0.000702	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—ALDH1A1—kidney cancer	5.14e-06	0.00069	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—LDHB—kidney cancer	5.13e-06	0.000688	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CTNNA1—kidney cancer	5.13e-06	0.000688	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—BCHE—kidney cancer	5.11e-06	0.000686	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—EIF4EBP1—kidney cancer	5.1e-06	0.000684	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—HSPB1—kidney cancer	5.1e-06	0.000684	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—SLC5A5—kidney cancer	5.05e-06	0.000678	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CTNNA1—kidney cancer	5.02e-06	0.000673	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—EIF4EBP1—kidney cancer	4.99e-06	0.000669	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—HSPB1—kidney cancer	4.99e-06	0.000669	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—SLC5A3—kidney cancer	4.93e-06	0.000661	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PGK1—kidney cancer	4.93e-06	0.000661	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—SLC2A1—kidney cancer	4.88e-06	0.000654	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—kidney cancer	4.88e-06	0.000654	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—LDHB—kidney cancer	4.84e-06	0.000649	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—TSC1—kidney cancer	4.74e-06	0.000636	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—PSMD7—kidney cancer	4.74e-06	0.000636	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—ANXA1—kidney cancer	4.74e-06	0.000636	CbGpPWpGaD
Metoprolol—SLC22A2—Transmembrane transport of small molecules—RAF1—kidney cancer	4.65e-06	0.000624	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—TSC1—kidney cancer	4.64e-06	0.000622	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—ANXA1—kidney cancer	4.64e-06	0.000622	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—PSMD7—kidney cancer	4.64e-06	0.000622	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—kidney cancer	4.61e-06	0.000619	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—FLT1—kidney cancer	4.59e-06	0.000616	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—CA9—kidney cancer	4.56e-06	0.000611	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—FLT1—kidney cancer	4.49e-06	0.000602	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—kidney cancer	4.49e-06	0.000602	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	4.46e-06	0.000598	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—CA9—kidney cancer	4.45e-06	0.000597	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—kidney cancer	4.39e-06	0.000589	CbGpPWpGaD
Metoprolol—ADRB1—GPCR downstream signaling—POMC—kidney cancer	4.33e-06	0.000581	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—JUNB—kidney cancer	4.26e-06	0.000571	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—PAK1—kidney cancer	4.26e-06	0.000571	CbGpPWpGaD
Metoprolol—ADRB2—GPCR downstream signaling—POMC—kidney cancer	4.24e-06	0.000568	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—CA9—kidney cancer	4.19e-06	0.000562	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—JUNB—kidney cancer	4.16e-06	0.000558	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—PAK1—kidney cancer	4.16e-06	0.000558	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—kidney cancer	4.15e-06	0.000556	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—GSTP1—kidney cancer	4.07e-06	0.000546	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—POMC—kidney cancer	3.93e-06	0.000527	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—CRABP1—kidney cancer	3.88e-06	0.00052	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—ABCB1—kidney cancer	3.85e-06	0.000517	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—POMC—kidney cancer	3.85e-06	0.000516	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—kidney cancer	3.81e-06	0.000511	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—CRABP1—kidney cancer	3.78e-06	0.000507	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—GSTM1—kidney cancer	3.74e-06	0.000502	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	3.69e-06	0.000494	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—ITPR2—kidney cancer	3.6e-06	0.000483	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—CRABP1—kidney cancer	3.57e-06	0.000478	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—CYP1A1—kidney cancer	3.55e-06	0.000475	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—ITPR2—kidney cancer	3.52e-06	0.000472	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—IGF2—kidney cancer	3.48e-06	0.000467	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CDKN2B—kidney cancer	3.46e-06	0.000465	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—IGF2—kidney cancer	3.4e-06	0.000456	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CDKN2B—kidney cancer	3.39e-06	0.000455	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—IGF1R—kidney cancer	3.36e-06	0.000451	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—POMC—kidney cancer	3.32e-06	0.000446	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—ITPR2—kidney cancer	3.31e-06	0.000444	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—IGF1R—kidney cancer	3.29e-06	0.000441	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—ACHE—kidney cancer	3.29e-06	0.000441	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—GSTT1—kidney cancer	3.29e-06	0.000441	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—RAF1—kidney cancer	3.24e-06	0.000435	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—GSTT1—kidney cancer	3.21e-06	0.00043	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—ACHE—kidney cancer	3.21e-06	0.00043	CbGpPWpGaD
Metoprolol—ADRB1—GPCR downstream signaling—IL2—kidney cancer	3.2e-06	0.000429	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—RAF1—kidney cancer	3.17e-06	0.000425	CbGpPWpGaD
Metoprolol—ADRB2—GPCR downstream signaling—IL2—kidney cancer	3.13e-06	0.00042	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—SCARB1—kidney cancer	3.11e-06	0.000417	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PTGS1—kidney cancer	3.08e-06	0.000413	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—SCARB1—kidney cancer	3.04e-06	0.000407	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—GSTT1—kidney cancer	3.02e-06	0.000405	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—ACHE—kidney cancer	3.02e-06	0.000405	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PSMD7—kidney cancer	3.02e-06	0.000405	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PTGS1—kidney cancer	3.01e-06	0.000403	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PSMD7—kidney cancer	2.95e-06	0.000395	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—IL2—kidney cancer	2.91e-06	0.00039	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—BCHE—kidney cancer	2.86e-06	0.000384	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—SCARB1—kidney cancer	2.86e-06	0.000384	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—IL2—kidney cancer	2.84e-06	0.000381	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PTGS1—kidney cancer	2.83e-06	0.00038	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—SLC5A5—kidney cancer	2.83e-06	0.000379	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—BCHE—kidney cancer	2.79e-06	0.000375	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PSMD7—kidney cancer	2.78e-06	0.000372	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—HIF1A—kidney cancer	2.77e-06	0.000371	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—TSC2—kidney cancer	2.76e-06	0.000371	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—SLC5A5—kidney cancer	2.76e-06	0.00037	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—SLC2A1—kidney cancer	2.73e-06	0.000366	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—HIF1A—kidney cancer	2.71e-06	0.000363	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—TSC2—kidney cancer	2.7e-06	0.000362	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—SLC2A1—kidney cancer	2.67e-06	0.000357	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	2.65e-06	0.000355	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—KDR—kidney cancer	2.65e-06	0.000355	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—POMC—kidney cancer	2.64e-06	0.000354	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—BCHE—kidney cancer	2.63e-06	0.000353	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—SLC5A5—kidney cancer	2.6e-06	0.000349	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—KDR—kidney cancer	2.59e-06	0.000347	CbGpPWpGaD
Metoprolol—ABCB1—Transmembrane transport of small molecules—RAF1—kidney cancer	2.54e-06	0.000341	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—SLC2A1—kidney cancer	2.51e-06	0.000337	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—KIT—kidney cancer	2.44e-06	0.000327	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—APC—kidney cancer	2.44e-06	0.000327	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—APC—kidney cancer	2.39e-06	0.00032	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—KIT—kidney cancer	2.39e-06	0.00032	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—MAPK3—kidney cancer	2.34e-06	0.000313	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—POMC—kidney cancer	2.32e-06	0.000311	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	2.31e-06	0.00031	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—BRAF—kidney cancer	2.29e-06	0.000308	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—MAPK3—kidney cancer	2.29e-06	0.000307	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—GSTP1—kidney cancer	2.28e-06	0.000305	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—POMC—kidney cancer	2.27e-06	0.000305	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—BRAF—kidney cancer	2.24e-06	0.000301	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—MAPK1—kidney cancer	2.22e-06	0.000298	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—GSTP1—kidney cancer	2.22e-06	0.000298	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—MAPK1—kidney cancer	2.17e-06	0.000292	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—ABCB1—kidney cancer	2.16e-06	0.000289	CbGpPWpGaD
Metoprolol—ADRB1—GPCR downstream signaling—PIK3CA—kidney cancer	2.12e-06	0.000285	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—PTGS2—kidney cancer	2.11e-06	0.000283	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—KRAS—kidney cancer	2.1e-06	0.000282	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—GSTP1—kidney cancer	2.09e-06	0.000281	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—GSTM1—kidney cancer	2.09e-06	0.000281	CbGpPWpGaD
Metoprolol—ADRB2—GPCR downstream signaling—PIK3CA—kidney cancer	2.08e-06	0.000279	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—KRAS—kidney cancer	2.05e-06	0.000276	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—GSTM1—kidney cancer	2.04e-06	0.000274	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—CYP1A1—kidney cancer	1.98e-06	0.000266	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—ABCB1—kidney cancer	1.98e-06	0.000266	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—CYP1A1—kidney cancer	1.94e-06	0.00026	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—PIK3CA—kidney cancer	1.93e-06	0.000259	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—GSTM1—kidney cancer	1.93e-06	0.000258	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—RAF1—kidney cancer	1.91e-06	0.000257	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—RELA—kidney cancer	1.91e-06	0.000256	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—ERBB2—kidney cancer	1.89e-06	0.000254	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—PIK3CA—kidney cancer	1.89e-06	0.000253	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—RAF1—kidney cancer	1.87e-06	0.000251	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—MTOR—kidney cancer	1.87e-06	0.000251	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—RELA—kidney cancer	1.86e-06	0.00025	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—ERBB2—kidney cancer	1.85e-06	0.000249	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—PTEN—kidney cancer	1.84e-06	0.000247	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—MTOR—kidney cancer	1.83e-06	0.000245	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—CYP1A1—kidney cancer	1.83e-06	0.000245	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CDKN1B—kidney cancer	1.75e-06	0.000235	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—IL2—kidney cancer	1.72e-06	0.00023	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CDKN1B—kidney cancer	1.72e-06	0.00023	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—IL2—kidney cancer	1.68e-06	0.000225	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CCND1—kidney cancer	1.67e-06	0.000224	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—JUN—kidney cancer	1.67e-06	0.000224	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CTNNB1—kidney cancer	1.66e-06	0.000222	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CCND1—kidney cancer	1.64e-06	0.00022	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—JUN—kidney cancer	1.63e-06	0.000219	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	1.63e-06	0.000219	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CTNNB1—kidney cancer	1.62e-06	0.000217	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—PTEN—kidney cancer	1.62e-06	0.000217	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—PTEN—kidney cancer	1.58e-06	0.000212	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—POMC—kidney cancer	1.48e-06	0.000198	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—VEGFA—kidney cancer	1.46e-06	0.000196	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—POMC—kidney cancer	1.44e-06	0.000194	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—VEGFA—kidney cancer	1.43e-06	0.000191	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—MAPK3—kidney cancer	1.38e-06	0.000185	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—POMC—kidney cancer	1.36e-06	0.000182	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—MAPK3—kidney cancer	1.35e-06	0.000181	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—MYC—kidney cancer	1.34e-06	0.00018	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—MAPK1—kidney cancer	1.31e-06	0.000176	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—MYC—kidney cancer	1.31e-06	0.000176	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—PIK3CA—kidney cancer	1.3e-06	0.000174	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—MAPK1—kidney cancer	1.28e-06	0.000172	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—KRAS—kidney cancer	1.24e-06	0.000166	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—KRAS—kidney cancer	1.21e-06	0.000163	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PTGS2—kidney cancer	1.18e-06	0.000158	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PTGS2—kidney cancer	1.15e-06	0.000154	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—PIK3CA—kidney cancer	1.14e-06	0.000153	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—PIK3CA—kidney cancer	1.11e-06	0.00015	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—TP53—kidney cancer	1.1e-06	0.000148	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PTGS2—kidney cancer	1.09e-06	0.000146	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—TP53—kidney cancer	1.08e-06	0.000145	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PTEN—kidney cancer	1.03e-06	0.000138	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PTEN—kidney cancer	1e-06	0.000135	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PTEN—kidney cancer	9.47e-07	0.000127	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PIK3CA—kidney cancer	7.26e-07	9.74e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PIK3CA—kidney cancer	7.09e-07	9.5e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PIK3CA—kidney cancer	6.68e-07	8.96e-05	CbGpPWpGaD
